GILD - Why Is HIV Drug Giant Gilead Stock Falling Monday? | Benzinga
Gilead Sciences Inc (NASDAQ:GILD) said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology.